Sotera Health Company (NASDAQ:SHC) Given Consensus Recommendation of “Moderate Buy” by Analysts

Sotera Health Company (NASDAQ:SHC) has received a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $20.25.

A number of analysts recently weighed in on the company. Piper Sandler restated an “overweight” rating and issued a $22.00 price target (down from $24.00) on shares of Sotera Health in a research note on Wednesday, May 6th. UBS Group set a $19.00 price objective on Sotera Health in a research report on Wednesday, June 24th. Barclays boosted their target price on shares of Sotera Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Sotera Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 11th. Finally, The Goldman Sachs Group assumed coverage on shares of Sotera Health in a report on Friday, June 5th. They issued a “buy” rating and a $20.00 price target for the company.

Insiders Place Their Bets

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total transaction of $193,194,516.17. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 15.36% of the company’s stock.

Institutional Investors Weigh In On Sotera Health

Several institutional investors have recently modified their holdings of SHC. Empowered Funds LLC increased its stake in Sotera Health by 11.1% in the 1st quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after purchasing an additional 2,845 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Sotera Health by 14.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock valued at $3,999,000 after purchasing an additional 43,471 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Sotera Health by 125.5% in the first quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock valued at $293,000 after buying an additional 14,018 shares in the last quarter. Creative Planning increased its position in shares of Sotera Health by 15.3% in the second quarter. Creative Planning now owns 20,186 shares of the company’s stock valued at $224,000 after buying an additional 2,673 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Sotera Health by 4.2% during the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock worth $3,549,000 after buying an additional 12,758 shares during the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Sotera Health Stock Performance

NASDAQ:SHC traded up $0.03 during mid-day trading on Friday, reaching $18.42. The stock had a trading volume of 2,304,888 shares, compared to its average volume of 2,442,119. Sotera Health has a twelve month low of $10.94 and a twelve month high of $19.85. The business has a 50 day simple moving average of $16.22 and a 200 day simple moving average of $16.39. The firm has a market capitalization of $5.25 billion, a price-to-earnings ratio of 44.93 and a beta of 1.76. The company has a debt-to-equity ratio of 3.56, a quick ratio of 2.54 and a current ratio of 2.82.

Sotera Health (NASDAQ:SHC) last released its earnings results on Tuesday, May 5th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.01. The company had revenue of $280.05 million for the quarter, compared to analysts’ expectations of $270.78 million. Sotera Health had a return on equity of 39.73% and a net margin of 9.91%.The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 EPS. Sotera Health has set its FY 2026 guidance at 0.930-1.010 EPS. On average, analysts expect that Sotera Health will post 0.87 earnings per share for the current fiscal year.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.